Alyssa M. Kaiser
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Alyssa M. Kaiser has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Arati Rajeevan
Division of Radiation and Cancer Biology, Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California
42 shared publications - Arielle Elkrief
Axe cancer, Centre de recherche du Centre Hospitalier de l’Université de Montréal (CRCHUM), Montréal, Canada
42 shared publications - Christopher T. Chen
Division of Oncology, Department of Medicine, Stanford University School of Medicine, 875 Blake Wilbur Drive, Palo Alto, CA, USA
42 shared publications - Colleen A. Brady
Division of Radiation and Cancer Biology, Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California
42 shared publications - Elsa R. Flores
Department of Molecular Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
42 shared publications - John H. Lockhart
Department of Molecular Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA
42 shared publications
Latest Publications
- Open Access
AP-1 specifies developmental versus fibrotic extracellular matrix transcriptional programs in the lung
Lung function requires an elastic extracellular matrix (ECM). However, the adult lung does not regenerate the elastic architecture established during development, and deposition of fibrous ECM characterizes many lung diseases. We generated a multimodal, single-nuclei atlas across development, homeostasis, aging, and fibrosis to identify lung fibroblast populations, transcriptional programs, and regulatory logic governing these divergent matrix outcomes. We discovered differential AP-1 transcription factor activity orchestrates distinct ECM programs via preferential binding to TPA-responsive elements (TRE) in fibrosis and cAMP-responsive elements (CRE) in development. Antagonizing AP-1 TRE-signaling in lung fibroblasts repressed the fibrotic program and re-engaged a developmental, elastogenic state, and MEK inhibition produced similar transcriptional phenotypes. Pathological fibroblasts in interstitial lung diseases upregulated TRE motif activity, and expression of downstream fibrosis signatures positively correlated with disease severity. These results uncover AP-1 as a critical signaling hub governing lung fibroblast ECM deposition that can potentially be exploited to improve disease outcomes.
Open AccessAP-1 specifies developmental versus fibrotic extracellular matrix transcriptional programs in the lung
Lung function requires an elastic extracellular matrix (ECM). However, the adult lung does not regenerate the elastic architecture established during development, and deposition of fibrous ECM characterizes many lung diseases. We generated a multimodal, single-nuclei atlas across development, homeostasis, aging, and fibrosis to identify lung fibroblast populations, transcriptional programs, and regulatory logic governing these divergent matrix outcomes. We discovered differential AP-1 transcription factor activity orchestrates distinct ECM programs via preferential binding to TPA-responsive elements (TRE) in fibrosis and cAMP-responsive elements (CRE) in development. Antagonizing AP-1 TRE-signaling in lung fibroblasts repressed the fibrotic program and re-engaged a developmental, elastogenic state, and MEK inhibition produced similar transcriptional phenotypes. Pathological fibroblasts in interstitial lung diseases upregulated TRE motif activity, and expression of downstream fibrosis signatures positively correlated with disease severity. These results uncover AP-1 as a critical signaling hub governing lung fibroblast ECM deposition that can potentially be exploited to improve disease outcomes.
- Open Access
- 9 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S10 from p53 Drives Lung Cancer Regression through a TSC2/TFEB-dependent Senescence Program
Supplementary Figure S10 shows that treatment of wild-type p53-expressing cells with an MDM2 antagonist across contexts.
- 9 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S10 from p53 Drives Lung Cancer Regression through a TSC2/TFEB-dependent Senescence Program
Supplementary Figure S10 shows that treatment of wild-type p53-expressing cells with an MDM2 antagonist across contexts.
- Open Access
- 9 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from p53 Drives Lung Cancer Regression through a TSC2/TFEB-dependent Senescence Program
Supplementary Figure S4 shows that p5353,54 restoration induces potent arrest.
- 9 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from p53 Drives Lung Cancer Regression through a TSC2/TFEB-dependent Senescence Program
Supplementary Figure S4 shows that p5353,54 restoration induces potent arrest.
- Open Access
- 9 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from p53 Drives Lung Cancer Regression through a TSC2/TFEB-dependent Senescence Program
Supplementary Figure S3 shows that restoration of p5353,54 in LUAD induces cell differentiation.
- 9 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from p53 Drives Lung Cancer Regression through a TSC2/TFEB-dependent Senescence Program
Supplementary Figure S3 shows that restoration of p5353,54 in LUAD induces cell differentiation.
- Open Access
- 9 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from p53 Drives Lung Cancer Regression through a TSC2/TFEB-dependent Senescence Program
Supplementary Figure S5 assesses transcriptional activities of p53 TAD mutants using RNA-seq.
- 9 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from p53 Drives Lung Cancer Regression through a TSC2/TFEB-dependent Senescence Program
Supplementary Figure S5 assesses transcriptional activities of p53 TAD mutants using RNA-seq.
- Open Access
- 9 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from p53 Drives Lung Cancer Regression through a TSC2/TFEB-dependent Senescence Program
List of genes upregulated with restoration of p53wt, relative to p53null cells.
- 9 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from p53 Drives Lung Cancer Regression through a TSC2/TFEB-dependent Senescence Program
List of genes upregulated with restoration of p53wt, relative to p53null cells.
- Open Access
- 9 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from p53 Drives Lung Cancer Regression through a TSC2/TFEB-dependent Senescence Program
Supplementary Figure S1 shows that p5353,54 restoration induces LUAD regression.
- 9 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from p53 Drives Lung Cancer Regression through a TSC2/TFEB-dependent Senescence Program
Supplementary Figure S1 shows that p5353,54 restoration induces LUAD regression.
- Open Access
- 9 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 6 from p53 Drives Lung Cancer Regression through a TSC2/TFEB-dependent Senescence Program
List of differentially expressed genes with restoration of p53wt that overlap with p53-bound genes.
- 9 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 6 from p53 Drives Lung Cancer Regression through a TSC2/TFEB-dependent Senescence Program
List of differentially expressed genes with restoration of p53wt that overlap with p53-bound genes.
- Open Access
- 9 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S8 from p53 Drives Lung Cancer Regression through a TSC2/TFEB-dependent Senescence Program
Supplementary Figure S8 shows that p5353,54 restoration induces TFEB nuclear translocation.
- 9 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S8 from p53 Drives Lung Cancer Regression through a TSC2/TFEB-dependent Senescence Program
Supplementary Figure S8 shows that p5353,54 restoration induces TFEB nuclear translocation.
- Open Access
- 9 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from p53 Drives Lung Cancer Regression through a TSC2/TFEB-dependent Senescence Program
List of genes upregulated with restoration of p5353,54, relative to p53null cells.
- 9 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from p53 Drives Lung Cancer Regression through a TSC2/TFEB-dependent Senescence Program
List of genes upregulated with restoration of p5353,54, relative to p53null cells.